Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis
- 1 November 1994
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 88 (6), 700-703
- https://doi.org/10.1016/0035-9203(94)90237-2
Abstract
The efficacy of aminosidine was compared with sodium stibogluconate in an open, randomized study of parasitologically-proven cutaneous leishmaniasis in Belize. Aminosidine, 14 mg/kg/d (max. 1 g daily) for 20 d, healed 10 of 17 lesions and sodium stibogluconate, 20 mg/kg/d for 20 d, healed 15 of 17 lesions. Lesions caused by Leishmania braziliensis were relatively unresponsive to aminosidine. Aminosidine was well tolerated and toxicity was not observed. Sodium stibogluconate was not well tolerated and treatment was associated with bone marrow suppression and elevation of serum aminotransferases.Keywords
This publication has 14 references indexed in Scilit:
- Recurrent cutaneous leishmaniasis: A role for persistent parasites?Parasitology Today, 1994
- Topical treatment of cutaneous leishmaniasis in belize: In vitro and in vivo studies with Leishmania mexicanaInternational Journal for Parasitology, 1993
- Practical progress and new drugs for changing patterns of leishmaniasisParasitology Today, 1993
- Cutaneous leishmaniasis in British troops from BelizeBritish Journal of Dermatology, 1993
- Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control studyJournal of the American Academy of Dermatology, 1992
- The Natural History of Cutaneous Leishmaniasis in GuatemalaThe Journal of Infectious Diseases, 1992
- Estimation of population at risk of infection and number of cases of LeishmaniasisParasitology Today, 1992
- Recurrent lesions in human Leishmania braziliensis infection—reactivation or reinfection?The Lancet, 1990
- Chemotherapy for Leishmaniasis: Biochemical Mechanisms, Clinical Efficacy, and Future StrategiesClinical Infectious Diseases, 1988
- SAFETY AND EFFICACY OF HIGH-DOSE SODIUM STIBOGLUCONATE THERAPY OF AMERICAN CUTANEOUS LEISHMANIASISThe Lancet, 1987